Vivos in The News Explore The Stories LeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Menu LeadershipFinancial Results & SEC FilingsStock PricingGovernanceNews + Events Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET. Replay of Fireside Chat Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET. Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The Market Under Nasdaq Rules Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea & Snoring Load More Vivos In The News Closing the Diagnosis Gap for Sleep Apnea with Wearables RNA in Oncology Research, Ultima Genomics Commercially Launches Platform Revolutionizing Sleep Apnea Diagnostics With Home Sleep Testing Solutions
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The Market Under Nasdaq Rules
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea & Snoring
